Journal of Materials Chemistry B



View Article Online

View Journal | View Issue

PAPER

Check for updates

Cite this: J. Mater. Chem. B, 2024, **12**, 1022

Synthetic macromolecular peptide-mimetics with amino acid substructure residues as protein stabilising excipients[†]

Ruggero Foralosso,^a Rafał Jerzy Kopiasz,^{ab} Cameron Alexander, ^b*^a Giuseppe Mantovani ^{*} and Snow Stolnik*^a

The clinical use of protein and peptide biotherapeutics requires fabrication of stable products. This particularly concerns stability towards aggregation of proteins or peptides. Here, we tested a hypothesis that interactions between a synthetic peptide, which is an aggregation-prone region analogue, and its homologous sequence on a protein of interest, could be exploited to design excipients which stabilise the protein against aggregation. A peptide containing the analogue of lysozyme aggregation-prone region (GILQINSRW) was conjugated to a RAFT agent and used to initiate the polymerisation of N-hydroxyethyl acrylamide, generating a GILQINSRW-HEA₉₀ polymer, which profoundly reduced lysozyme aggregation. Substitution of tryptophan in GILQINSRW with glycine, to form GILQINSRG, revealed that tryptophan is a critical amino acid in the protein stabilisation by GILQINSRW-HEAgo. Accordingly, polymeric peptide-mimetics of tryptophan, phenylalanine and isoleucine, which are often present in aggregation-prone regions, were synthesized. These were based on synthetic oligomers of acrylamide derivatives of indole-3 acetic acid (IND), phenylacetic acid (PHEN), or 2-methyl butyric acid (MBA), respectively, conjugated with hydrophilic poly(N-hydroxyethyl acrylamide) blocks to form amphiphilic copolymers denoted as IND_m -, $PHEN_m$ - and MTB_m -b-HEA_n. These materials were tested as protein stabilisers and it was shown that solution properties and the abilities of these materials to stabilise insulin and the peptide IDR 1018 towards aggregation are dependent on the chemical nature of their side groups. These data suggest a structure-activity relationship, whereby the indole-based IND_mb-HEA_n peptide-mimetic displays properties of a potential stabilising excipient for protein formulations.

Received 9th September 2023, Accepted 27th December 2023

DOI: 10.1039/d3tb02102e

rsc.li/materials-b

Introduction

The translation of proteins or peptides from biotechnology to biotherapeutic products offers potential treatments to a variety of diseases with unmet clinical need. The rationale for these biomolecules as therapeutics stems from their known mode of action, their inherent degradability as well as typical 'drug attributes' such as specificity and potency. This translation from an often complex and delicate macromolecule towards a medicine however requires fabrication of a stable product. This particularly concerns stability towards aggregation of protein or peptide molecules – the process by which unfolded molecules adopt a conformation that causes their clustering into aggregates or/and fibrils.¹ Hence, solutions are required to ensure stability to different stress factors during all stages of development and use of peptide or protein formulations. There are currently over 130 protein biotherapeutics in clinical practice, covering disease indications from diabetes, haemophilia, multiple sclerosis, hepatitis C and many cancers.² These employ a range of stabilising strategies, including: addition of low-molecular weight compounds like amino acids glycine, proline and histidine,³ sugars like trehalose and sucrose, or polyols such as sorbitol. Covalent attachment of polyethylene glycol (PEG) to therapeutic proteins is another option which provides formulation stabilisation, and which can also impact positively on in vivo performance. PEGylated colony-stimulating factors, interferons, erythropoietin and mAbs⁴⁻⁶ are biotherapeutic products that have already reached clinical application. An alternative strategy is a non-covalent PEGylation of a protein, for example as shown by the use of cholanic acid-PEG to increase the half-life of recombinant human growth hormone (rh-GH) and recombinant human granulocyte colony stimulating factor (rh-G-CSF) in vivo,7,8 and tryptophan-PEG was used to

^a University of Nottingham, School of Pharmacy, NG7 2RD, UK.

E-mail: giuseppe.mantovani@nottingham.ac.uk, snow.stolnik@nottingham.ac.uk, cameron.alexander@nottingham.ac.uk

^b Warsaw University of Technology, Faculty of Chemistry, Noakowskiego 3 St., 00-664, Warsaw, Poland

[†] Electronic supplementary information (ESI) available. See DOI: https://doi.org/

^{10.1039/}d3tb02102e

Paper

reduce significantly the aggregation of salmon calcitonin *in vitro*.⁹ In a related context, mPEG_{2k}-poly(glutamic acid) copolymers have been utilised to form reversible protein complexes formulated for application to the lung.¹⁰ Synthetic copolymers containing carbohydrate pendant units, especially trehalose-based, have also been used to reduce/modulate protein aggregation.¹¹⁻¹⁴

The aggregation of many protein or peptide molecules can be attributed to the existence of 5-15 amino acid long regions that display high hydrophobicity, low net charge, and a high tendency to form β -structures. These are usually termed aggregation-prone regions (APR), and have been shown to be responsible for the aggregation of a range of proteins.^{15,16} APRs are typically buried within a protein's hydrophobic core and/or positioned close to the active site of enzymes or polypeptide ligands,^{17,18} and the aggregation process is normally initiated by their exposure to the solvent. Protein unfolding, caused by stress factors (e.g. temperature or pH), or intrinsic factors (e.g. destabilisation of the native structure by genetic mutation) can expose the amino acid sequence of the APR and initiate their self-assembly and consequent protein aggregation. Disruption of APR self-assembly has thus been investigated as an approach to prevent the formation of amyloid aggregates by endogenous proteins, observed to occur in neurodegenerative diseases such as Alzheimer's.¹⁹ It has been suggested that synthetic peptides, termed β -sheet breakers, could be developed to be capable of binding the amyloid precursor $\alpha\beta$ fragment, but unable to self-assemble into a β -sheet structure.²⁰ Such peptides have been shown to prevent aggregation of the $\alpha\beta$ peptide into amyloid fibrils in vitro.21-25

The starting premise of this study was that a stabilizing excipient could be designed comprising a peptide with an amino acid sequence analogous to that of APR, in order to bind strongly to an 'unfolding protein' on the path to aggregation, but with a hydrophilic chain conjugated to the peptide in order to provide a steric barrier towards protein aggregation. This approach might be considered analogous to bioconjugation and PEGylation strategies, but with an 'associative linker' rather than a conjugate, which interfered in the kinetics of aggregation by blocking access to an intermediate in the protein fragment self-association pathway. The protein lysozyme, and the peptide Gly-Ile-Leu-Gln-Ile-Asn-Ser-Arg-Trp (GIL-QINSRW) previously identified as the aggregation-prone region in lysozyme,²⁶ were selected as a model system. The GIL-QINSRW peptide was synthesized, incorporated into a RAFT chain-transfer agent (CTA), which was used to mediate the polymerisation of N-hydroxyethylacrylamide (HEA), forming the required hydrophilic block. Initial experiments identified the crucial role of tryptophan (Trp/W) amino acid of the GILQINSRW sequence in the stabilisation of lysozyme towards aggregation. We then further focused on the synthesis of a tryptophan peptide-mimetic based on indole - a side group of tryptophan, with the aim to test if such a synthetic material could achieve a stabilising effect comparable to that of tryptophan in a peptide or polymer sequence. Accordingly, RAFT CTAs incorporating indole oligomers were synthesised and used to mediate the polymerisation of HEA as a hydrophilic block.

For comparison, and to assess if a structure–activity relationship could be established, we also synthesized peptide-mimetics of two other amino acids normally present in APRs, phenylalanine (Phe/F) and isoleucine (Ile/I) – based on phenylacetic acid, and methyl butyric acid structures, respectively. The resulting materials were compared for their ability to moderate the aggregation of insulin and the anti-microbial peptide, IDR 1018,²⁷ as representative therapeutic biomolecules, and promising initial activities of these materials were obtained.

Results and discussion

Peptide-HEA conjugations synthesis

To investigate the possibility for stabilising lysozyme with peptides analogue of its APR region, short peptide Gly-Ile-Leu-Gln-Ile-Asn-Ser-Arg-Trp (GILQINSRW, residues 54–62)²⁶ was synthesised. Interestingly, Tokunaga et al. have shown that the GILQINSRW fragment of lysozyme APR self-assembles through mutual β-sheet interactions, but a single amino acid substitution of tryptophan with glycine (GILQINSRG) completely suppresses the aggregation.²⁸ Hence, to gain further insight to whether GILQINSRW peptide impacts on the aggregation of lysozyme via an interaction of its GILQINSRW sequences with APR, an analogous peptide Gly-Ile-Leu-Gln-Ile-Asn-Ser-Arg-Gly (GILQINSRG) was also synthesised. Both GILQINSRW and GILQINSRG peptides were prepared by solid-state peptide synthesis on 2-chlorotrityl chloride resin using Fmoc-protected amino acids (Fig. 1(a) and Section S3 in ESI[†]). Additionally, to (i) circumvent water solubility issues and selfaggregation of the peptide itself,²⁸ and (ii) provide steric stabilisation against aggregation of the protein molecules once GILQINSRW and GILQINSRG were able to interact with lysozyme, the linkage of the peptides with a very hydrophilic polymer chain was carried out. In these cases, poly(N-hydroxyethyl acrylamide) (pHEA) and the peptide-polymer conjugates HEA₉₀-GILQINSRW (1) and HEA₉₅-GILQINSRG (2), were also obtained (Fig. 1(a)). This process involved coupling of a 4-cyano-4-(((ethylthio)carbonothioyl)thio)pentanoic acid, as a chain transfer agent (CTA), to the resin-bound peptides (1a and 2a) and subsequent cleavage from the resin to obtain GILQINSRW- and GILQINSRG-RAFT agents 1b and 2b (Fig. 1(a)). These agents were subsequently used to mediate the RAFT polymerisation of HEA, followed by cleavage of the amino acid protecting groups giving the final materials HEA90-GILQINSRW (1) and HEA95-GILQINSRG (2). The obtained polymer-peptide conjugates, as well as RAFT agents 1b and 2b, were characterised by ¹H NMR spectroscopy and HR-MS (Fig. 1(c) and Fig. S1-S11, ESI⁺), which confirmed their structure and purity. Conjugates 1 and 2 were additionally characterised by size-exclusion chromatography (SEC) (Table 1). Additionally, poly(N-hydroxyethyl acrylamide) without additional functionalities (HEA100) was synthesised as control polymers as shown in Fig. 1(b) (characterisation data in Table 1).

Moderation of lysozyme aggregation

We tested the potential of HEA_{90} -GILQINSRW to stabilize lysozyme in an alkaline medium which induces its aggregation.




Fig. 1 (a) Synthesis of HEA₉₀-GILQINSRW, and HEA₉₅-GILQINSRG; (b) synthesis of HEA_n as control polymers; (c) ¹H NMR (400 MHz, DMSO-d₆) spectra of obtained GILQINSRW-HEA₉₀ conjugation. Reagents and conditions: (a) DMF, DIPEA, rt; (b) DMF, piperidine, rt; (c) DMF, Fmoc-amino acid, HATU, DIPEA, rt; (d) CTA, HATU, TEA, DMF, rt; (e) DCM/TFE 8:2 v/v, rt; (f) *N*-hydroxyethyl acrylamide, V501, DMF, 70 °C; (g) AIBN, DMF, 80 °C; (h) 0.1 N HCl in hexafluoro-2-propanol (HFIP), rt.

Table 1	Composition,	M _n ,	and	dispersity	of	obtained	peptides	and
polyHEA								

Composition	$M_{ m n,THEO}^{a}$	(kDa) $M_{n,NMR}$ (k	Da) $M_{n,SEC}^{c}$ (l	kDa) Đ
HEA90-GILQINSRW (1) 10.5	10.8^{b}	17.0	1.09
HEA95-GILQINSRG (2) 10.3	12.1^{b}	14.8	1.13
HEA100	7.6	—	12.1	1.14

Composition is indicated by numbers in subscript. ^{*a*} Calculated from initial [HEA]:[CTA] and final monomer conversion. ^{*b*} Number of repeating units of HEA calculated from ¹H NMR spectra by comparing the integral of peptides' methyl groups with the hydroxyl peak of HEA repeating units. ^{*c*} Obtained from SEC in DMF + 0.1% LiBr (PMMA standards).

While the peptide GILQINSRW was insoluble in water, the polymer-peptide conjugate was freely soluble in both water and in phosphate buffer up to the highest tested concentration of 0.035 mg mL⁻¹. Accordingly, phosphate buffer was chosen as an appropriate medium for the lysozyme aggregation studies, in this case at a pH of 12.3 with assays conducted at room temperature, as these are conditions known to denature lysozyme.^{29,30} This approach assumes that these conditions promote unfolding of the protein exposing its APR, which

makes it more accessible to APR from other lysozyme protein molecules and to the APR-like sequence from HEA_{90} -GILQINSRW.

The results of the lysozyme aggregation study are shown in Fig. 2 and confirm the formation of large aggregates in control samples containing only lysozyme. Conversely, in the presence of HEA₉₀-GILQINSRW (1:1 mol with respect to lysozyme) the onset of aggregation was delayed by 10 hours, and within 24 hours




Fig. 2 Aggregation assay for lysozyme (10 mg mL⁻¹) in the presence of HEA₉₀-GILQINSRW, HEA₉₅-GILQINSRG, and HEA₁₀₀ in 100 mM phosphate buffer pH 12.3; molar ratio of peptides and HEA₁₀₀ to lysozyme was 1:1. Lysozyme aggregation assessed by turbidimetry at λ = 500 nm, readings were taken every 30 min for 24 h.

Paper

of the experiment the aggregation remains relatively low. The profiles further indicated an increased rate of aggregation in the presence of the HEA100 homopolymer, which is analogous to HEA90-GILQINSRW but lacks the GILQINSRW peptide block. This may be ascribed to the macromolecular crowding induced by the simultaneous presence in solution of two macromolecules, the protein and the polymer, at relatively high concentration (10 mg mL⁻¹ lysozyme, 9 mg mL⁻¹ HEA₁₀₀) and the 'excluded volume' occupied by the polymer increasing the chances of protein-protein interaction and precipitation.^{29,30} The aggregation profile of HEA₉₅-GILQINSRG shows that it does not modulate lysozyme aggregation. On the contrary, it appears that HEA95-GILQINSRG causes an increase in the rate of aggregation, similar to the control polymer HEA100, further indicating the absence of associative interactions with the protein-aggregation region.

These data indicate that the modification of a single amino acid in the peptide sequence from GILQINSRW to GILQINSRG suppresses interaction of the corresponding HEA₉₅-GILQINSRG conjugate with lysozyme, in line with the reported loss of selfaggregation of the GILQINSRW peptide when its terminal W is replaced with G residue.²⁸ This suggests that the stabilisation effect of HEA₉₀-GILQINSRW may be attributed to the specific interaction between its GILQINSRW moiety and the homologous aggregation-prone region on lysozyme. The results further highlight the decisive role of tryptophan to maintain antiaggregation properties of the GILQINSRW sequence.

Synthesis of copolymeric peptide-mimetics

After identifying the key role of tryptophan in the HEA₉₀-GILQINSRW stabilisation of lysozyme (Fig. 2), we synthesised tryptophan peptide-mimetic block copolymers based on indole-3 acetic acid (Fig. 3(a)), acknowledging that the pendant indole group defines many physico-chemical properties of tryptophan.³¹ As other hydrophobic amino acids, like phenylalanine and isoleucine, play an important role in the protein aggregation process and are abundant in APRs of many proteins, our studies on peptide mimetics were extended to include block copolymers containing phenyl and iso-butyl groups, as mimics of the side chains of these amino acids (Fig. 3(a)).

As the first step, acrylic monomers IND, PHEN, and MTB were obtained *via* coupling of *N*-hydroxyethyl acrylamide with indole-3 acetic acid, phenylacetic acid, and methylbutyric acid, respectively (Scheme S3 and Section S5.1 in the ESI†). Then, these monomers were polymerised by RAFT polymerisation, to synthesise hydrophobic oligomeric chain transfer agents (CTAs) IND_m, PHEN_m, and MTB_m (m = 1, 3, 10, Fig. 3(a) and Section S5.2 in ESI†). Purification of the oligomeric CTAs with m = 1 and m = 3 was carried out by flash chromatography, in analogy with the purification of discrete oligomers on silica described by Hawker and co-workers,³² whereas CTAs with average m = 10 were used as obtained from the RAFT reaction, without the additional chromatographic step.

Subsequently, the oligomeric CTAs were used to mediate the RAFT polymerisation of *N*-hydroxyethyl acrylamide, aiming at degrees of polymerisation (DP) of 40 and 100, to investigate the

influence of the size of the polyHEA block on protein–copolymer interaction. The resulting block copolymers IND_m -*b*-HEA_n, PHEN_m-*b*-HEA_n, MTB_m-*b*-HEA_n were characterised using ¹H NMR spectroscopy and SEC (Fig. 3(b)–(d), Table 2, and Section S5.3 in the ESI†). A small shoulder at higher molar masses was in the observed in the SEC traces of IND_n -*b*-HEA_m block copolymers, which may be ascribable to a small extent of bimolecular coupling termination, which can occur in RAFT polymerisation.³³ The discrepancy between number average molar mass determined by ¹H NMR ($M_{n,NMR}$) and SEC ($M_{n,SEC}$) may result from differences in polymer hydrodynamic volume compared to the standards employed for calibration of SEC.

Characterisation of block copolymer self-assemblies

The synthesised IND_{m} , PHEN_m, and MTB_{m} -b-HEA_n copolymers are amphiphilic molecules consisting of a hydrophobic and a hydrophilic block. Therefore, to further characterise them, their ability to self-assemble in aqueous environment was investigated by dynamic light scattering (Fig. 4 and Table 3).

Data for IND_m , $PHEN_m$ and MTB_m -HEA_n with m = 1 and 3 show average hydrodynamic particle diameters $D_{\rm h}$ of around 3-5 nm for shorter HEA_n ($n \approx 37$), and of around 5–7 nm for longer HEA_n ($n \approx 100$), with polydispersity indices representative of a relatively narrow particles size distribution. This is consistent with the presence of highly hydrated individual chains of these copolymers in a solvated extended conformation. For instance, the gyration radius of free PEG with molecular mass within the range of 2 kDa to 15 kDa ranging from 1.3 nm to 4 nm.^{34,35} However, IND₁₀- and PHEN₁₀-*b*-HEA_n show significantly higher hydrodynamic diameters of around 10 nm for shorter HEA_n ($n \approx 40$), and 12–14 nm for longer HEA_n $(n \approx 100)$. Interestingly, there is no measurable increase in diameter of MTB_{10} -*b*-HEA_{*n*} for either *n* = 43 or 105 in comparison with MTB1- and MTB3-. Taken together, these data indicate minimal or no aggregation in water of copolymers with m =1 and 3, whilst a prolongation of the hydrophobic block content to 10 repeating units for indole- and phenyl-containing materials induces self-association into species of about 10-14 nm in size, with relatively narrow size distributions, as indicated by their PDI values. A possible explanation for this observation is an intermolecular interaction between aromatic indole and phenyl rings (e.g. π -stacking), which is not present in the case of the branched aliphatic methyl butyryl residues of MTB_m-b-HEA_n copolymers.

Further analysis of self-assembly behaviour of IND_3 and IND_{10} -*b*-HEA_n molecules in water by surface tension (γ) measurements indicates that the former copolymer is a weak whereas the latter a strong surfactant, reducing γ to 66 mN m⁻¹ and 58 mN m⁻¹, respectively (Fig. 5). The γ vs. concentration plot for IND_{10} -*b*-HEA_n presents a formation of supramolecular aggregates at a concentration between 1.0 and 2.0 mg mL⁻¹ (critical aggregation concentration, CAC). In the case of IND_3 -*b*-HEA₉₈, the γ vs. concentration plot has no clear discontinuity or plateau at higher concentrations. This result agrees with our DLS analysis results (Table 3) that indicate an absence of selfassembled species for IND_3 -*b*-HEA₉₈.






Fig. 3 (a) Synthesis of IND_m^- , $PHEN_m^-$, $MTB_m^-b^-HEA_n$ block copolymers. Reagents and conditions: (a) AIBN, CTA, DMF, 80 °C; (b) *N*-hydroxyethyl acrylamide, V501, DMF, 70 °C; (b) ¹H NMR (DMSO-d₆, 400 MHz) spectrum of IND_3 -HEA₉₅ as a representative spectrum of the synthesised block copolymers; SEC chromatograms of $IND_m^-b^-HEA_n$ copolymers with (c) shorter and (d) longer hydrophilic blocks, using DMF with 0.1% LiBr as the mobile phase. Spectra and SEC chromatograms of all polymers are shown in Sections S5.3.1 and S5.3.2 in the ESI.†

Table 2	$M_{\rm n}$ and dispersity of IND _m	-, PHEN _m -, MTB _m -b-HEA _n	materials synthesised in this work
	11 · · · · · · · · · · · · · · · · · ·		

Composition	$M_{\rm n,THEO}^{a}$ (kDa)	$M_{\mathrm{n,NMR}}$ (kDa)	$M_{n,SEC}^{e}$ (kDa)	Đ	Composition	$M_{\rm n,THEO}^{a}$ (kDa)	$M_{\mathrm{n,NMR}}$ (kDa)	$M_{n,SEC}^{e}$ (kDa)	Đ
IND ₁ - <i>b</i> -HEA ₃₇	5.5	5.0^{b}	8.7	1.07	IND ₁ - <i>b</i> -HEA ₁₀₀	9.0	8.7 ^b	13	1.08
PHEN ₁ -b-HEA ₃₇	5.1	4.8^{c}	9.0	1.07	PHEN ₁ -b-HEA ₁₀₀	12	12.2^{c}	18.6	1.08
MTB ₁ - <i>b</i> -HEA ₃₇	5.9	4.8^{d}	10.4	1.05	MTB ₁ - <i>b</i> -HEA ₁₁₁	13.1	13.2^{d}	19.8	1.09
IND ₃ -b-HEA ₅₃	5.4	6.7 ^b	11.7	1.09	IND ₃ - <i>b</i> -HEA ₉₈	11.5	12^b	17	1.11
PHEN ₃ -b-HEA ₄₅	5.4	6.2^{c}	9.6	1.07	PHEN ₃ -b-HEA ₉₉	11.7	12.5^{c}	17.5	1.06
MTB ₃ -b-HEA ₄₂	6.4	7.3^{d}	10.9	1.05	MTB ₃ -b-HEA ₈₂	10.2	10.5^{d}	16.8	1.07
IND ₁₀ -b-HEA ₄₀	6.1	7.7 ^b	10.5	1.15	IND10-b-HEA95	10.7	14.1^{b}	18.4	1.11
PHEN ₁₀ -b-HEA ₃₈	6.8	7.0 ^c	10.7	1.08	PHEN ₁₀ -b-HEA ₈₈	12.6	12.9 ^c	17.4	1.07
MTB ₁₀ - <i>b</i> -HEA ₄₃	6.7	7.2^{d}	10.0	1.07	MTB ₁₀ - <i>b</i> -HEA ₁₀₅	12.5	15.0^{d}	18.7	1.07
HEA ₃₆	4.5		8.5	1.04	HEA ₁₀₀	13		12.1	1.14

^{*a*} Calculated from initial [HEA]:[CTA] and final monomer conversion. ^{*b*} Number of repeating units of HEA monomers calculated by ¹H NMR, in DMSO-d₆, by comparing the integral of indole aromatic. ^{*c*} Number of repeating units of HEA monomers calculated by ¹H NMR, in DMSO-d₆, by comparing the integral of methylene. ^{*d*} Number of repeating units of HEA monomers calculated by ¹H NMR, in DMSO-d₆, by comparing the integral of methylene. ^{*d*} Number of repeating units of HEA monomers calculated by ¹H NMR, in DMSO-d₆, by comparing the integral of methylene. ^{*d*} Number of repeating units of HEA monomers calculated by ¹H NMR, in DMSO-d₆, by comparing the integral of methylenes with the hydroxyl peak of HEA repeating units. ^{*e*} Obtained from SEC in DMF + 0.1% LiBr (PMMA standards).




Fig. 4 Size distribution (volume%) of copolymers' self-assemblies (1 mg mL⁻¹) in DI water as determined by DLS

Table 3 Hydrodynamic diameter measured by DLS of IND_m -, $PHEN_m$ -, and MTB_m -*b*-HEA_n copolymers reported from volume distribution. Polydispersity indices are provided in brackets; materials were analysed at 1.0 mg mL⁻¹ in DI water

Polymer:	IND ₁ - <i>b</i> -HEA ₃₇	PHEN ₁ - <i>b</i> -HEA ₃₇	MTB ₁ - <i>b</i> -HEA ₃₇	IND ₁ - <i>b</i> -HEA ₁₀₀	PHEN ₁ -b-HEA ₁₀₀	MTB ₁ - <i>b</i> -HEA ₁₁₁
Size (PDI) nm	4.43 (0.26)	3.28 (0.62)	3.15 (0.36)	6.05 (0.11)	5.69 (0.05)	6.81 (0.43)
Polymer: Size (PDI) nm	IND_3 - <i>b</i> -HEA ₅₃ 5.54 (0.18)	$\begin{array}{l}\text{MTB}_{3}\text{-}b\text{-HEA}_{42}\\ 3.53\ (0.07)\end{array}$	MTB ₃ - <i>b</i> -HEA ₄₂ 4.73 (1.62)	IND_3 - <i>b</i> -HEA ₉₈ 5.21 (0.27)	PHEN ₃ - <i>b</i> -HEA ₉₉ 6.23 (0.86)	$\begin{array}{l} \text{MTB}_{3}\text{-}b\text{-HEA}_{82} \\ 5.40 \ (1.0) \end{array}$
Polymer: Size (PDI) nm	IND ₁₀ - b -HEA ₄₀ 9.73 (016)	PHEN ₁₀ - <i>b</i> -HEA ₃₈ 9.71 (0.18)	$\begin{array}{l} \text{MTB}_{10}\text{-}b\text{-HEA}_{43} \\ \text{6.54 (0.20)} \end{array}$	IND_{10} - <i>b</i> -HEA ₉₅ 14.28 (0.15)	PHEN ₁₀ - b -HEA ₈₈ 12.03 (0.16)	$\begin{array}{l}\text{MTB}_{10}\text{-}b\text{-HEA}_{105}\\ 5.38\ (0.33)\end{array}$

Modulation of insulin aggregation by block copolymers

After identifying the key role of tryptophan in the HEA₉₀-GILQINSRW stabilisation of lysozyme, we studied tryptophan peptide-mimetic oligomers based on indole-3 acetic acid (IND_m *b*-HEA_n), on the basis that the indole ring contributes the defining physicochemical properties of tryptophan.³¹ Unfortunately, under the alkaline conditions that induce lysozyme aggregation, IND_m -, PHEN_m- and MTB_m-*b*-HEA_n materials failed to show any stabilizing effect (Fig. S32 and S33, Section S6 in ESI[†]). Further analysis revealed that these aggregation favouring conditions (pH 12.3) induce hydrolysis of the ester groups linking the pendant indole group to the polymer backbone; the ¹H NMR spectrum of IND_{10} -*b*-HEA after incubation under such conditions displayed no indole aromatic protons peaks between 6.9–7.3 ppm (Spectrum S34, Section S6 in the ESI[†]).

Accordingly, we selected insulin as a model protein to replace lysozyme in the aggregations studies as it is well-established that

the aggregation of insulin is initiated at pH around 5.3, corresponding to the protein isoelectric point.37 The residues of insulin B-chain including GB8, SB9, VB12, EB13, YB16, GB23, FB24, FB25, YB26, and TB27 are believed to play an important role in insulin self-assembly.38 The impact of the peptidemimetic materials synthesized in this work on the aggregation of insulin is shown in Fig. 6. Only 17% of insulin (0.34 mg mL⁻¹ out of 2 mg mL⁻¹) remained in a solution after incubation at conditions inducing its aggregation. However, the addition of IND₃- and IND₁₀-b-HEA_m polymers at polymer: peptide molar ratio of 10 prevented aggregation very efficiently - almost 100% of insulin remained in its non-aggregated state after 20 h. Conversely, this effect was not observed for IND₁-b-HEA_n which possesses only one indole group. For PHEN_m-based copolymers, only the longest copolymer, PHEN10-b-HEA88, reduces aggregation (61% non-aggregated insulin retained), when compared to HEA₁₀₀ control polymers (only 24% of residual insulin in solution).




Fig. 5 Surface tension measurements of representative copolymers IND₃-b-HEA₉₈ and IND₁₀-b-HEA₉₅ carried out in water by pendant drop method.³⁶




Fig. 6 Insulin aggregation in the presence of IND_m -, $PHEN_m$ - and MTB_m -*b*-HEA_n materials. Concentration of insulin remaining in a solution after incubation in the aggregation inducing conditions (pH 5.2) for 20 h without and with synthesised copolymers at different molar ratio; the initial concentration of insulin was 2 mg mL⁻¹. Higher values in the graph correspond to better protein stabilisation and hence reduced aggregation.

No measurable impact against insulin aggregation is seen for copolymers containing isoleucine-mimicking groups – MTB_m -*b*-HEA_n.

Interaction of peptide-mimetic oligomers with insulin.

In the next step potential effects of the IND_{10} -based oligomers on the secondary structure of insulin were assessed by circular dichroism (CD). The analysis of samples in the presence of IND_{10} -*b*-HEA₉₅ produced poor signal-to-noise ratio, likely due to the presence of indole groups, as reported previously.³⁹ The analysis hence measured the CD profile after separation of insulin and IND_{10} -*b*-HEA₉₅. Whilst this experiment cannot inform directly on secondary structure alterations that may be occurring during insulin interactions with stabilizing IND_{10} -*b*-HEA₉₅, it however provides an insight to whether these interactions induce irreversible changes of the protein secondary structure (Fig. S31, ESI†). The profile obtained from the 'native' insulin, *i.e.* before any manipulation, exhibits two negative peaks, at 208 nm and 222 nm, as previously described for bovine insulin, and is typical of an α -helix secondary structure.⁴⁰ A similar profile is seen for the sample subjected to HPLC purification. The two samples taken from insulin aggregation experiments in the presence of IND₁₀-*b*-HEA₉₅ at 10:1 and 5:1 insulin molar ratios also show [θ] *vs.* wavelength profiles similar to that of native insulin. The experiment hence indicates that the stabilizing IND₁₀-*b*-HEA₉₅ peptide-mimetic does not cause irreversible changes in the protein secondary structure.

Moderation of IDR 1018 aggregation by block copolymers

To exemplify the potential of our synthetic peptide-mimetic materials to moderate aggregation of peptides, the IDR 1018 peptide, consisting of the amino acid sequence VRLIVAV-RIWRR was selected. This peptide has been reported to show antimicrobial and immunomodulatory activities,⁴¹⁻⁴³ but clinical applications have been hampered by its tendency to




Fig. 7 The concentration of IDR 1018 remaining in a solution after incubation in aggregation conditions (100 mM phosphate buffer, pH 7.2) for 5 h without and with synthesised copolymers at 1:1 molar ratio; the initial concentration of the peptide was 0.153 mg mL⁻¹. Higher values in the graph correspond to better protein stabilisation and hence reduced aggregation.

aggregation under aqueous conditions. This aggregation has been attributed to the 5 consecutive hydrophobic residues between L3 and V7, which are believed to form the peptide's aggregation-prone region. The effect of IND_m ⁻, $PHEN_m$ -, and MTB_m -*b*-HEA_n materials on aggregation of the peptide was investigated in 100 mM pH 7.2 phosphate buffer, where IDR 1018 is known to aggregate,⁴⁴ and the results are presented in Fig. 7.

Incubation of IDR 1018 in 100 mM phosphate buffer, pH 7.2 for 5 hours resulted in 75% peptide aggregation – 38.3 mg mL⁻¹ final concentration from an initial 153 mg L⁻¹. However, in the presence of indole-based materials (IND₃-*b*-HEA₅₃, IND₁₀-*b*-HEA₄₀, IND₃-*b*-HEA₉₈ and IND₁₀-*b*-HEA₉₅) in a 1:1 (co)polymer: IDR 1018 molar ratio, as much as 70–80% of the peptide remained in solution under identical conditions, whereas for phenyl-based materials (PHEN₁₀-*b*-HEA₃₈ and PHEN₁₀-*b*-HEA₁₀₀) it was around 50–75%. The other copolymers tested did not show any stabilization effect on IDR 1018 (Fig. 7).

Data on behaviour of IND_{10} - and $PHEN_{10}$ -b-HEA_n copolymers in aqueous solutions (Table 3 and Fig. 4 and 5), together with protein aggregation results (Fig. 6 and 7), could be explained with the existence of an equilibrium between polymer self-assemblies and their interactions with the proteins and peptides tested, leading to their stabilization towards aggregation. This is apparent for IND_{10} -HEA_n and $PHEN_{10}$ -b-HEA_n materials. Interestingly, similar protein stabilization induced by IND_3 -b-HEA_n and IND_{10} -b-HEA_n may suggest that polymer self-assembly does not hamper interactions with proteins, as the former one does not self-assemble (Fig. 5).

Collectively, the data indicate different impacts of copolymers bearing indole, phenyl, or methyl butyric side groups mimicking W, F, and I, respectively, on protein stabilisation. This observation may be ascribed to the physicochemical properties of tryptophan, strongly affected by its indole ring, observed via the influence of tryptophan on protein folding, as well as its positioning in lipid bilayers and in the membranespanning regions of transmembrane proteins. Tryptophan has a number of unique molecular features:⁴⁵ the largest nonpolar (hydrophobic) area of all amino acids due to the two-sided π -electron face of its indole side chain that is also polarizable and highly accessible because of its planar topology, the strongest electrostatic potential for cation- π interactions, and an indole hydrogen-bond donor N-H moiety. The single phenyl ring, present in phenylalanine and PHEN_m-b-HEA_n copolymers, nor the short branched alkyl group present in isoleucine and MTB_m -b-HEA_n, do not exhibit the full range of these properties, hence their interactions with protein regions involved with the aggregation of the proteins and peptide tested may be limited. Furthermore, the presented data indicate to exert a protein stabilizing activity IND_m-b-HEA_n copolymers must comprise more than one indole-containing repeating unit (IND), as a tryptophan mimetic unit. Intriguingly, a PEG_{2k}-tryptophan conjugate reported by Mueller et al.46 has shown a significant stabilization effect on salmon calcitonin despite bearing only a single tryptophan unit, thus indicating that that the structure of tryptophan-containing stabilisers may need fine-tuning to

achieve the desired protein/peptide stabilisation effect. Importantly, the proteins and peptides tested to date with tryptophan-containing stabilisers – lysozyme, insulin, IDR 1018, and salmon calcitonin – possess chemically distinct aggregation-prone regions (APRs), which underlines the versatility of indole moiety in protein stabilization.

Conclusions

This work started with a hypothesis that interactions could be exploited between a synthetic peptide, which is an aggregationprone region analogue, and its homologous sequence on a protein, to design excipients to stabilise the protein against aggregation. The hypothesis further suggested that attachment of a hydrophilic polymer to such a peptide will provide a stabilisation effect, such that the associative interactions at the aggregation-prone region of the peptide mimetic with the protein would prevent full aggregation by the steric demands of the attached hydrophilic polymer. The synthesized GILQINSRW-HEA₉₀ polymer containing the lysozyme aggregation-prone region analogue indeed shows a dramatic reduction in lysozyme aggregation. Substitution of tryptophan in GILQINSRW with glycine to form GILQINSRG showed, via the lack of activity of the mutated peptide, that tryptophan was a decisive factor in the protein stabilisation by GILQINSRW-b-HEA90. This led to the successful synthesis of peptide-mimetics from tryptophan, phenylalanine and isoleucine amino acid analogues, based on synthetic oligomers of indole-3 acetic acid, phenylacetic acid, or methylbutyric acid, and with a block of poly(HEA) to provide aqueous solubility and steric stabilisation: IND_m-, PHEN_m- and MTB_m -*b*-HEA_n. The study then demonstrates that the solution properties and their ability of these materials to stabilise insulin and IDR 1018 peptide towards aggregation are dependent on the chemical nature of their side groups - indole vs. phenyl vs. methylbutyrate - with indole based IND_m-b-HEA_n peptidemimetic material displaying properties of a potential stabilising excipient to protein formulations.

Experimental section

For materials, synthetic procedures and analytical methods see the ESI.†

Author contributions

Ruggero Foralosso – investigation, methodology, formal analysis. Rafal Kopiasz – formal analysis, writing – original draft, writing – review and editing. Giuseppe Mantovani – supervision, writing – review and editing. Cameron Alexander – funding acquisition, supervision, writing – review and editing. Snow Stolnik – funding acquisition, supervision, writing – review and editing.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was funded by the Engineering and Physical Science Research Council [EP/L01646X/1] and the Royal Society [Wolfson Research Merit Award WM150086 to CA]. We thank Dr Marco di Antonio (University of Cambridge) for conducting the circular dichroism experiments. We also thank Tom Hyde, Esme Ireson and Paul Cooling for expert technical support.

References

- 1 M. Stefani, Biochim. Biophys. Acta, Mol. Basis Dis., 2004, 1739, 5-25.
- 2 M. Evans, P. M. Schumm-Draeger, J. Vora and A. B. King, *Diabetes, Obes. Metab.*, 2011, **13**, 677–684.
- 3 S. Saurabh, C. Kalonia, Z. Li, P. Hollowell, T. Waigh, P. Li, J. Webster, J. M. Seddon, J. R. Lu and F. Bresme, *Mol. Pharmaceutics*, 2022, **19**, 3288–3303.
- 4 M. J. Roberts, M. D. Bentley and J. M. Harris, *Adv. Drug Delivery Rev.*, 2002, **54**, 459–476.
- 5 P. L. Turecek, M. J. Bossard, F. Schoetens and I. A. Ivens, *J. Pharm. Sci.*, 2016, **105**, 460–475.
- 6 F. M. Veronese and G. Pasut, *Drug Discovery Today*, 2005, **10**, 1451–1458.
- 7 S. Salmaso, S. Bersani, F. Mastrotto, G. Tonon, R. Schrepfer, S. Genovese and P. Caliceti, *J. Controlled Release*, 2012, 162, 176–184.
- 8 S. Salmaso, S. Bersani, A. Scomparin, A. Balasso, C. Brazzale, M. Barattin and P. Caliceti, *J. Controlled Release*, 2014, **194**, 168–177.
- 9 C. Mueller, M. A. H. Capelle, E. Seyrek, S. Martel, P.-A. Carrupt, T. Arvinte and G. Borchard, J. Pharm. Sci., 2012, 101, 1995–2008.
- A. Nieto-Orellana, M. Di Antonio, C. Conte, F. H. Falcone, C. Bosquillon, N. Childerhouse, G. Mantovani and S. Stolnik, *Polym. Chem.*, 2017, 8, 2210–2220.
- 11 R. J. Mancini, J. Lee and H. D. Maynard, J. Am. Chem. Soc., 2012, 134, 8474-8479.
- 12 J. Madeira do O, F. Mastrotto, N. Francini, S. Allen, C. F. van der Walle, S. Stolnik and G. Mantovani, *J. Mater. Chem. B*, 2018, **6**, 1044–1054.
- 13 M. Milewska, A. Milewski, I. Wandzik and M. H. Stenzel, *Polym. Chem.*, 2022, **13**, 1831–1843.
- A. N. Bristol, J. Saha, H. E. George, P. K. Das, L. K. Kemp, W. L. Jarrett, V. Rangachari and S. E. Morgan, *Biomacromolecules*, 2020, 21, 4280–4293.
- 15 J. Beerten, J. Schymkowitz and F. Rousseau, *Curr. Top. Med. Chem.*, 2013, **12**, 2470–2478.
- 16 Aggregation of Therapeutic Proteins, ed. W. Wang and C. J. Roberts, John Willey & Sons, Inc., New Jersey, 2010.
- 17 G. De Baets, J. Schymkowitz and F. Rousseau, *Essays Biochem.*, 2014, **56**, 41–52.
- 18 A.-M. Fernandez-Escamilla, F. Rousseau, J. Schymkowitz and L. Serrano, *Nat. Biotechnol.*, 2004, **22**, 1302–1306.
- 19 A. Aguzzi and T. O'Connor, *Nat. Rev. Drug Discovery*, 2010, **9**, 237–248.
- 20 S. C. Li, N. K. Goto, K. A. Williams and C. M. Deber, Proc. Natl. Acad. Sci. U. S. A., 1996, 93, 6676–6681.
- 21 C. Soto, M. S. Kindy, M. Baumann and B. Frangione, *Biochem. Biophys. Res. Commun.*, 1996, **226**, 672–680.

- 22 C. Soto, E. M. Sigurdsson, L. Morelli, R. Asok Kumar, E. M. Castaño and B. Frangione, *Nat. Med.*, 1998, 4, 822–826.
- 23 C. Adessi and C. Soto, Drug Dev. Res., 2002, 56, 184-193.
- 24 L. O. Tjernberg, D. J. E. Callaway, A. Tjernberg, S. Hahne, C. Lilliehöök, L. Terenius, J. Thyberg and C. Nordstedt, *J. Biol. Chem.*, 1999, 274, 12619–12625.
- 25 W. P. Esler, E. R. Stimson, J. R. Ghilardi, Y.-A. Lu, A. M. Felix, H. V. Vinters, P. W. Mantyh, J. P. Lee and J. E. Maggio, *Biochemistry*, 1996, 35, 13914–13921.
- 26 Y. Sugimoto, Y. Kamada, Y. Tokunaga, H. Shinohara, M. Matsumoto, T. Kusakabe, T. Ohkuri and T. Ueda, *Biochem. Cell Biol.*, 2011, 89, 533–544.
- 27 S. C. Mansour, C. de la Fuente-Núñez and R. E. W. Hancock, *J. Pept. Sci.*, 2015, 21, 323–329.
- 28 Y. Tokunaga, Y. Sakakibara, Y. Kamada, K. Watanabe and Y. Sugimoto, *Int. J. Biol. Sci.*, 2013, **9**, 219–227.
- 29 I. Kuznetsova, K. Turoverov and V. Uversky, Int. J. Mol. Sci., 2014, 15, 23090–23140.
- 30 I. Kuznetsova, B. Zaslavsky, L. Breydo, K. Turoverov and V. Uversky, *Molecules*, 2015, 20, 1377–1409.
- 31 T. Bar and Y. Okon, *Can. J. Microbiol.*, 2011, **39**, 81–86, DOI: 10.1139/m93-011.
- 32 J. Lawrence, S.-H. Lee, A. Abdilla, M. D. Nothling, J. M. Ren, A. S. Knight, C. Fleischmann, Y. Li, A. S. Abrams, B. V. K. J. Schmidt, M. C. Hawker, L. A. Connal, A. J. McGrath, P. G. Clark, W. R. Gutekunst and C. J. Hawker, *J. Am. Chem. Soc.*, 2016, **138**, 6306–6310.
- 33 S. Perrier, Macromolecules, 2017, 50, 7433-7447.
- 34 F. Piguet, H. Ouldali, F. Discala, M. F. Breton, J. C. Behrends, J. Pelta and A. Oukhaled, *Sci. Rep.*, 2016, 6, 38675, DOI: 10.1038/srep38675.
- 35 K. Devanand and J. C. Selser, *Asymptotic Behavior and Long-Range Interactions in Aqueous Solutions of Polyethylene oxide*, 1991, vol. 24.
- 36 C. E. Stauffer, J. Phys. Chem., 1965, 69, 1933-1938.
- 37 F. Fischel-Ghodsian, L. Brown, E. Mathiowitz, D. Brandenburg and R. Langer, *Proc. Natl. Acad. Sci. U. S. A.*, 1988, 85, 2403–2406.
- 38 A. Das, M. Shah and I. Saraogi, ACS Bio Med Chem Au, 2022, 2, 205–221.
- 39 D. Andersson, U. Carlsson and P.-O. Freskgård, *Eur. J. Biochem.*, 2001, **268**, 1118–1128.
- 40 J. Goldman and F. H. Carpenter, Biochemistry, 1974, 13, 4566-4574.
- 41 O. M. Pena, N. Afacan, J. Pistolic, C. Chen, L. Madera, R. Falsafi,
 C. D. Fjell and R. E. W. Hancock, *PLoS One*, 2013, 8, e52449.
- 42 H. Choe, A. S. Narayanan, D. A. Gandhi, A. Weinberg, R. E. Marcus, Z. Lee, R. A. Bonomo and E. M. Greenfield, *Clin. Orthop. Relat. Res.*, 2015, **473**, 2898–2907.
- 43 M. Wieczorek, H. Jenssen, J. Kindrachuk, W. R. P. Scott, M. Elliott, K. Hilpert, J. T. J. Cheng, R. E. W. Hancock and S. K. Straus, *Chem. Biol.*, 2010, **17**, 970–980.
- 44 E. F. Haney, B. (Catherine) Wu, K. Lee, A. L. Hilchie and R. E. W. Hancock, *Cell. Chem. Biol.*, 2017, 24, 969–980.e4.
- 45 D. E. Schlamadinger, J. E. Gable and J. E. Kim, *J. Phys. Chem. B*, 2009, **113**, 14769–14778.
- 46 C. Mueller, M. A. H. Capelle, T. Arvinte, E. Seyrek and G. Borchard, *Eur. J. Pharm. Biopharm.*, 2011, **79**, 646–657.